
Ulocuplumab
CAS No. 1375830-34-4
Ulocuplumab ( —— )
产品货号. M36724 CAS No. 1375830-34-4
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) 是一种完全人 IgG4 抗 CXCR4 抗体。Ulocplumab 诱导癌细胞凋亡 (apoptosis),能够抑制 CXCL12 介导的慢性淋巴细胞白血病 (CLL) 细胞在 CXCR4 激活下的迁移。Ulocplumab 在急性髓系白血病 (AML),非霍奇金淋巴瘤 (NHL) 和多发性骨髓瘤移植模型中显示抗肿瘤活性。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥3191 | 有现货 |
![]() ![]() |
5MG | ¥5717 | 有现货 |
![]() ![]() |
10MG | ¥7970 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Ulocuplumab
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) 是一种完全人 IgG4 抗 CXCR4 抗体。Ulocplumab 诱导癌细胞凋亡 (apoptosis),能够抑制 CXCL12 介导的慢性淋巴细胞白血病 (CLL) 细胞在 CXCR4 激活下的迁移。Ulocplumab 在急性髓系白血病 (AML),非霍奇金淋巴瘤 (NHL) 和多发性骨髓瘤移植模型中显示抗肿瘤活性。
-
产品描述Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.
-
体外实验Apoptosis Analysis Cell Line:Ramos cells and primary leukemia cells (from CLL patients)Concentration:0-100 μM Incubation Time:48 hours Result:Induced apoptosis in Ramos cells with an IC50 value of 1.9 nM and showed pro-apoptotic with an IC50 value of 12.43 nM in primary leukemia cells from CLL patients.
-
体内实验Animal Model:Severe combined immunodeficient (SCID) mice of AML model (MOLP-8 cells) Dosage:3-30 mg/kg Administration:Intraperitoneal injection; every 3-4 days for 5 doses; last for 65 days Result:Significantly delayed mean tumor growth by 66% and 56% when compared with isotype control on day 25.
-
同义词——
-
通路Autophagy
-
靶点CXCR
-
受体CXCR | Apoptosis
-
研究领域——
-
适应症——
化学信息
-
CAS Number1375830-34-4
-
分子量146.2 (kDa)
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kashyap MK, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7(3):2809-22. ?
产品手册




关联产品
-
AD80
AD80 是一种多激酶抑制剂,可抑制 RET、RAF、SRC 和 S6K,并大大降低 mTOR 活性。
-
Delmetacin
Delmetacin (Demethacin) is a non-steroidal anti-inflammatory compound with anti-inflammatory and analgesic activity and inhibitory effects on the CXC chemokine receptor CXCR1.
-
Cefoselis Sulfate
头孢塞利是一种广泛使用的 β-内酰胺抗生素。